ProShare Advisors’s NeoGenomics NEO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $149K | Sell |
20,081
-5,005
| -20% | -$52.7K | ﹤0.01% | 1649 |
|
|
2025
Q4 | $295K | Buy |
25,086
+780
| +3% | +$8.41K | ﹤0.01% | 1467 |
|
|
2025
Q3 | $188K | Sell |
24,306
-4,503
| -16% | -$31.5K | ﹤0.01% | 1706 |
|
|
2025
Q2 | $211K | Sell |
28,809
-1,232
| -4% | -$9.94K | ﹤0.01% | 1693 |
|
|
2025
Q1 | $285K | Sell |
30,041
-8,404
| -22% | -$105K | ﹤0.01% | 1448 |
|
|
2024
Q4 | $634K | Buy |
38,445
+11,831
| +44% | +$184K | ﹤0.01% | 1139 |
|
|
2024
Q3 | $393K | Buy |
26,614
+6,995
| +36% | +$109K | ﹤0.01% | 1288 |
|
|
2024
Q2 | $272K | Sell |
19,619
-6,064
| -24% | -$86K | ﹤0.01% | 1354 |
|
|
2024
Q1 | $404K | Buy |
25,683
+1,765
| +7% | +$27.3K | ﹤0.01% | 1224 |
|
|
2023
Q4 | $387K | Buy |
23,918
+4,526
| +23% | +$74.1K | ﹤0.01% | 1210 |
|
|
2023
Q3 | $239K | Sell |
19,392
-513
| -3% | -$7.63K | ﹤0.01% | 1355 |
|
|
2023
Q2 | $320K | Buy |
19,905
+1,644
| +9% | +$27.1K | ﹤0.01% | 1237 |
|
|
2023
Q1 | $318K | Sell |
18,261
-1,618
| -8% | -$23K | ﹤0.01% | 1180 |
|
|
2022
Q4 | $184K | Buy |
19,879
+2,579
| +15% | +$24K | ﹤0.01% | 1519 |
|
|
2022
Q3 | $149K | Sell |
17,300
-2,270
| -12% | -$22.5K | ﹤0.01% | 1468 |
|
|
2022
Q2 | $159K | Sell |
19,570
-8,797
| -31% | -$84K | ﹤0.01% | 1527 |
|
|
2022
Q1 | $344K | Sell |
28,367
-3,356
| -11% | -$70.6K | ﹤0.01% | 1530 |
|
|
2021
Q4 | $1.08M | Buy |
31,723
+11,114
| +54% | +$435K | ﹤0.01% | 977 |
|
|
2021
Q3 | $994K | Sell |
20,609
-12,013
| -37% | -$556K | ﹤0.01% | 915 |
|
|
2021
Q2 | $1.47M | Buy |
32,622
+133
| +0.4% | +$5.89K | ﹤0.01% | 836 |
|
|
2021
Q1 | $1.57M | Buy |
32,489
+7,144
| +28% | +$372K | ﹤0.01% | 779 |
|
|
2020
Q4 | $1.36M | Buy |
25,345
+10,650
| +72% | +$481K | 0.01% | 755 |
|
|
2020
Q3 | $542K | Sell |
14,695
-1,225
| -8% | -$45.5K | ﹤0.01% | 911 |
|
|
2020
Q2 | $493K | Buy |
15,920
+8,654
| +119% | +$240K | ﹤0.01% | 952 |
|
|
2020
Q1 | $201K | Sell |
7,266
-8,528
| -54% | -$255K | ﹤0.01% | 1012 |
|
|
2019
Q4 | $462K | Buy |
15,794
+2,305
| +17% | +$54.9K | ﹤0.01% | 1105 |
|
|
2019
Q3 | $258K | Buy |
13,489
+1,858
| +16% | +$43.6K | ﹤0.01% | 1303 |
|
|
2019
Q2 | $255K | Sell |
11,631
-14
| -0.1% | -$307 | ﹤0.01% | 1322 |
|
|
2019
Q1 | $238K | Buy |
+11,645
| New | +$202K | ﹤0.01% | 1369 |
|
|
2014
Q2 | – | Sell |
-33,300
| Closed | -$116K | – | 2552 |
|
|
2014
Q1 | $116K | Buy |
+33,300
| New | +$125K | ﹤0.01% | 2669 |
|
|
2013
Q4 | – | Sell |
-20,773
| Closed | -$62K | – | 1675 |
|
|
2013
Q3 | $62K | Buy |
+20,773
| New | +$58.5K | ﹤0.01% | 2490 |
|
Other funds holding NEO
FLAM
GF
VPM
VCM
B
ProShare Advisors's NEO Position: Q1 2026 in Review
ProShare Advisors reduced its NeoGenomics (NEO) stake by 20% in Q1 2026, selling an estimated $52.7K and leaving 20,081 shares worth $149K. The position accounts for ﹤0.01% of the portfolio, ranked #1649.
ProShare Advisors first reported a position in NEO in Q3 2013 and has held it in 31 quarters since. The position peaked at $1.57M in Q1 2021. 253 funds tracked by Wall St. Rank hold NEO as of Q1 2026.
- ProShare Advisors held 20,081 shares of NeoGenomics worth $149K as of Q1 2026.
- ProShare Advisors sold 5,005 NeoGenomics shares in Q1 2026, an estimated $52.7K.
- NeoGenomics made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1649 holding.
- ProShare Advisors first reported a position in NeoGenomics in Q3 2013 and has held it in 31 quarters since.
- ProShare Advisors's NeoGenomics position peaked at $1.57M in Q1 2021.
- 253 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2026.
Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.